NerPharMa - Part of NMS Group
Hugues Dolgos serves as the Chief Executive Officer of NMS Group since January 2022, overseeing its mission to enhance patient health through innovative drug research and development, particularly in oncology. Simultaneously, Hugues holds the position of Chairperson of the Board at Accelera, a Contract Research Organization focused on advancing drug candidates. Hugues also leads as Chairperson of the Board and CEO at both NerPharMa and Nerviano Medical Sciences, driving advancements in drug development and delivery for complex health needs. Previously, Hugues held significant roles at Servier and Merck Group, influencing oncology progression and R&D strategy. Hugues's educational background includes studies at Université Paris Cité.
This person is not in any teams
This person is not in any offices
NerPharMa - Part of NMS Group
NerPharMa operates as a Contract Development and Manufacturing Organization and is characterized by a strong specialization in oncology with important know-how and the highest quality standards. More than 100 selected and specialized employees working at NerPharMa, in two different teams: NerPharMa DP dealing with the development and manufacturing of compounds, injectables and solid oral for various therapeutic areas, with handling of cytotoxic and cytostatic finished products and activities of formulation, packaging and distribution and NerPharMa DS dealing with the development and production of active principles only oncological moving from laboratory scale to commercial products.